Literature DB >> 19343300

Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with advanced non-small cell lung cancer.

Chia-Chi Lin1, Chih-Hsin Yang.   

Abstract

Elderly and poor performance status advanced non-small cell lung cancer (NSCLC) patients often tolerate chemotherapy poorly. Special approaches are needed for these patient populations. Tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR), erlotinib and gefitinib, are active agents in the treatment of advanced NSCLC. Several phase II trials have been conducted utilizing EGFR TKIs in elderly or poor performance status patients with advanced NSCLC. This review will summarize the results of erlotinib or gefitinib in these subsets of patients with advanced NSCLC.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19343300     DOI： 10.1007/s11523-009-0104-2

Source DB:  PubMed          Journal:  Target Oncol        ISSN： 1776-2596            Impact factor:   4.493


  58 in total

1.  Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer.

Authors:  Chih-Hsin Yang; Jin-Yuan Shih; Kun-Chieh Chen; Chong-Jen Yu; Tsung-Ying Yang; Ching-Pei Lin; Wen-Pin Su; Chien-Hung Gow; Chiun Hsu; Gee-Chen Chang; Pan-Chyr Yang
Journal:  Cancer       Date:  2006-10-15       Impact factor: 6.860

2.  TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

Authors:  Roy S Herbst; Diane Prager; Robert Hermann; Lou Fehrenbacher; Bruce E Johnson; Alan Sandler; Mark G Kris; Hai T Tran; Pam Klein; Xin Li; David Ramies; David H Johnson; Vincent A Miller
Journal:  J Clin Oncol       Date:  2005-07-25       Impact factor: 44.544

3.  Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study.

Authors:  Alex Chang; Purvish Parikh; Sumitra Thongprasert; Eng Huat Tan; Reury-Perng Perng; Domingo Ganzon; Chih-Hsin Yang; Chao-Jung Tsao; Claire Watkins; Nick Botwood; Nick Thatcher
Journal:  J Thorac Oncol       Date:  2006-10       Impact factor: 15.609

4.  Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599.

Authors:  Corey Langer; Sigui Li; Joan Schiller; William Tester; Bernardo L Rapoport; David H Johnson
Journal:  J Clin Oncol       Date:  2007-02-01       Impact factor: 44.544

5.  Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors.

Authors:  Charles Erlichman; Manuel Hidalgo; Joseph P Boni; Patricia Martins; Susan E Quinn; Charles Zacharchuk; Peter Amorusi; Alex A Adjei; Eric K Rowinsky
Journal:  J Clin Oncol       Date:  2006-05-20       Impact factor: 44.544

6.  A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC).

Authors:  K Roszkowski; A Pluzanska; M Krzakowski; A P Smith; E Saigi; U Aasebo; A Parisi; N Pham Tran; R Olivares; J Berille
Journal:  Lung Cancer       Date:  2000-03       Impact factor: 5.705

7.  Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.

Authors:  Federico Cappuzzo; Fred R Hirsch; Elisa Rossi; Stefania Bartolini; Giovanni L Ceresoli; Lynne Bemis; Jerry Haney; Samir Witta; Kathleen Danenberg; Irene Domenichini; Vienna Ludovini; Elisabetta Magrini; Vanesa Gregorc; Claudio Doglioni; Angelo Sidoni; Maurizio Tonato; Wilbur A Franklin; Lucio Crino; Paul A Bunn; Marileila Varella-Garcia
Journal:  J Natl Cancer Inst       Date:  2005-05-04       Impact factor: 13.506

8.  Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer.

Authors:  Pasi A Jänne; Joachim von Pawel; Roger B Cohen; Lucio Crino; Charles A Butts; Steven S Olson; Irene A Eiseman; Alberto A Chiappori; Beow Y Yeap; Peter F Lenehan; Kathy Dasse; Meredith Sheeran; Philip D Bonomi
Journal:  J Clin Oncol       Date:  2007-09-01       Impact factor: 44.544

9.  Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

Authors:  Giuseppe Giaccone; Roy S Herbst; Christian Manegold; Giorgio Scagliotti; Rafael Rosell; Vincent Miller; Ronald B Natale; Joan H Schiller; Joachim Von Pawel; Anna Pluzanska; Ulrich Gatzemeier; John Grous; Judith S Ochs; Steven D Averbuch; Michael K Wolf; Pamela Rennie; Abderrahim Fandi; David H Johnson
Journal:  J Clin Oncol       Date:  2004-03-01       Impact factor: 44.544

10.  Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer.

Authors:  Riichiroh Maruyama; Yutaka Nishiwaki; Tomohide Tamura; Nobuyuki Yamamoto; Masahiro Tsuboi; Kazuhiko Nakagawa; Tetsu Shinkai; Shunichi Negoro; Fumio Imamura; Kenji Eguchi; Koji Takeda; Akira Inoue; Keisuke Tomii; Masao Harada; Noriyuki Masuda; Haiyi Jiang; Yohji Itoh; Yukito Ichinose; Nagahiro Saijo; Masahiro Fukuoka
Journal:  J Clin Oncol       Date:  2008-09-10       Impact factor: 44.544
View more
  3 in total

1.  Durable complete remission of poor performance status metastatic lung adenocarcinoma patient treated with second-line erlotinib: a case report.

Authors:  Dragana Jovanovic; Ruza Stevic; Marta Velinovic; Milica Kontic; Dragana Maric; Jelena Spasic; Davorin Radosavljevic
Journal:  Onco Targets Ther       Date:  2017-09-06       Impact factor: 4.147

2.  An observational study to evaluate factors predicting survival in patients of non-small cell lung cancer with poor performance status in resource-constrained settings.

Authors:  Akhil Kapoor; Vanita Noronha; Amit Joshi; Vijay M Patil; Nandini Menon; Rajesh Bollam; Vikas Talreja; Supriya Goud; Sucheta More; Leena Solanki; Srushti Shah; Anuradha Chougule; Abhishek Mahajan; Kumar Prabhash
Journal:  Ecancermedicalscience       Date:  2021-08-05

3.  Clinical study on gefitinib combined with γ-ray stereotactic body radiation therapy as the first-line treatment regimen for senile patients with adenocarcinoma of the lung (final results of JLY20080085).

Authors:  Dejian Pan; Biao Wang; Xijian Zhou; Donglin Wang
Journal:  Mol Clin Oncol       Date:  2013-05-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.